Boeckmans Joost, Buyl Karolien, Natale Alessandra, Vandenbempt Valerie, Branson Steven, De Boe Veerle, Rogiers Vera, De Kock Joery, Rodrigues Robim M, Vanhaecke Tamara
Department of In Vitro Toxicology & Dermato-Cosmetology (IVTD), Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel. Laarbeeklaan 103, 1090 Brussels, Belgium.
Department of Urology, UZ Brussel. Laarbeeklaan 101, 1090 Brussels, Belgium.
Data Brief. 2019 Jun 3;25:104093. doi: 10.1016/j.dib.2019.104093. eCollection 2019 Aug.
The present dataset contains the transcriptomic characterization of a novel model of non-alcoholic steatohepatitis (NASH) as well as its transcriptomics read-outs for the evaluation of elafibranor, a potential anti-NASH compound. We report whole genome microarray data (Affymetrix HG U133 plus 2.0) of human multipotent stem cell-derived hepatic cells (hSKP-HPC) exposed to mediators of NASH. These cells were exposed to lipogenic inducers (insulin, glucose, fatty acids) and pro-inflammatory factors (IL-1β, TNF-α, TGF-β) to trigger hepatocellular responses characteristic of NASH. In addition, to evaluate the anti-NASH features of elafibranor, a dual peroxisome proliferator-activated receptor (PPAR) agonist that currently is under investigation as a potential anti-NASH therapeutic, was tested this set-up. This paper provides a detailed description of the microarray data as well as an indication of their value for evaluating cell signaling pathways ( NFκB network) during the evaluation of anti-NASH compounds. Raw microarray data of different testing conditions were deposited as.CEL files in the Gene Expression Omnibus of NCBI with GEO Series accession number GSE126484. Further interpretation and discussion of these data can be found in the corresponding research article (DOI: 10.1016/j.phrs.2019.04.016) Boeckmans et al., 2019.
本数据集包含一种新型非酒精性脂肪性肝炎（NASH）模型的转录组学特征，以及用于评估潜在抗NASH化合物艾拉非布的转录组学读数。我们报告了暴露于NASH介质的人多能干细胞衍生肝细胞（hSKP-HPC）的全基因组微阵列数据（Affymetrix HG U133 plus 2.0）。这些细胞暴露于脂肪生成诱导剂（胰岛素、葡萄糖、脂肪酸）和促炎因子（IL-1β、TNF-α、TGF-β）以触发NASH特征性的肝细胞反应。此外，为了评估艾拉非布的抗NASH特性，在该实验设置中测试了一种双过氧化物酶体增殖物激活受体（PPAR）激动剂，目前该激动剂正在作为一种潜在的抗NASH治疗药物进行研究。本文详细描述了微阵列数据，并指出了它们在评估抗NASH化合物过程中评估细胞信号通路（NFκB网络）的价值。不同测试条件下的原始微阵列数据以.CEL文件形式存放在NCBI的基因表达综合数据库中，GEO系列登录号为GSE126484。这些数据的进一步解读和讨论可在相应的研究文章（DOI：10.1016/j.phrs.2019.04.016）Boeckmans等人，2019年中找到。
